The third-quarter earnings season reveals a sector at a crossroads. While government and technical consulting firms like Jacobs Solutions benefit from long-term structural trends, their latest financial results and market reactions paint a complex picture of resilience and recalibration.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
Driven by falling costs and strong incentives, heavy manufacturing is increasingly turning to on-site solar power. This shift is transforming large factory roofs from passive structures into strategic assets for cutting energy bills and emissions.
Cavco Industries (CVCO) reported robust first-quarter fiscal 2026 earnings, with revenue climbing 9.5% year-over-year and operating profit jumping approximately 50%. The manufactured housing leader credited strategic production increases, improved pricing, and a rebound in its financial services segment for the strong performance, while also highlighting its pending acquisition of American Homestar.
Deere & Company is doubling down on American manufacturing with a new excavator plant and parts center, part of a broader $20 billion commitment. While the move strengthens its long-term industrial narrative, near-term challenges from leadership changes to cyclical market pressures remain in focus.
Facing ongoing labor disputes, Starbucks unveils a massive investment in new espresso machines, AI-assisted POS systems, and a store rating program aimed at streamlining operations and improving the partner experience.
Despite significant institutional purchases and regulatory progress, Bitcoin continues to drift lower, leading analysts and investors to question what price level will finally stem the tide.
A new report reveals a staggering 67% of purchased sales software features go unused, spotlighting a critical disconnect between tech spending and revenue impact. As IT budgets swell, C-suite leaders are urged to shift from measuring adoption to calculating true dollar-for-dollar returns.
Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.
In a significant policy shift, Chinese authorities have reportedly cleared the AI startup DeepSeek to purchase Nvidia's advanced H200 processors, potentially easing a major hardware bottleneck for its competitive large language model.
Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
Canadian National Railway reported improved revenue and operating income for the fourth quarter of 2025, citing productivity gains and recovery from prior-year port disruptions. However, the company issued a cautious outlook for 2026, forecasting 'flattish' freight volumes as U.S.-Canada trade tensions and a major regulatory review loom.
Paramount Skydance has appointed seasoned Capitol Hill and private sector strategist Ted Lehman as its top U.S. policy executive, a move signaling an intensified government relations focus as the media giant navigates a complex merger landscape and regulatory battles.
Longtime CMO Jon Bridges steps down as Chick-fil-A enters its 80th anniversary year. Michael Lage, a 14-year company veteran with digital and operations experience, will take the helm after a transition period.
HSBC has raised its rating on New Oriental Education & Technology Group (NYSE: EDU) from 'Hold' to 'Buy', following the company's better-than-expected Q2 FY2026 results. The upgrade highlights a robust recovery in core businesses and strategic expansion into new educational initiatives.
New unemployment filings in Wisconsin edged higher last week, diverging from a slight national decline and highlighting ongoing labor market fluctuations across states.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
As XRP enters a historically weak month, conflicting signals from whale accumulation, ETF flows, and exchange deposits set the stage for a volatile February 2026. Analysts pinpoint key levels that will determine the token's near-term trajectory.
Gentex Corporation (GNTX) reported a 19% surge in Q4 2025 revenue to $644.4 million, bolstered by its VOXX acquisition. While core auto-dimming mirror sales held steady, the company achieved a significant five-point outperformance in its primary markets and hit its highest gross margin target since 2021, showcasing resilience against tariff pressures and setting a confident growth trajectory for 2026.
Despite posting quarterly results that beat analyst expectations, KLA Corporation's stock plunged Friday as investors focused on management warnings about component shortages, tariff impacts, and operational constraints.
